Circulating Tumor Cells Enhance Prognostic Stratification Beyond ER Assessment by Biopsy or FES-PET in Endocrine-Treated Metastatic Breast Cancer.
Saved in:
| Title: | Circulating Tumor Cells Enhance Prognostic Stratification Beyond ER Assessment by Biopsy or FES-PET in Endocrine-Treated Metastatic Breast Cancer. |
|---|---|
| Authors: | Eisses B; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands., Angus L; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GE Rotterdam, The Netherlands., Kuip EJM; Department of Medical Oncology, Radboud Medical Center, 6500 HK Nijmegen, The Netherlands., Menke-van der Houven van Oordt CW; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, 1081 HV Amsterdam, The Netherlands., van der Vegt B; Department of Pathology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands., Glaudemans AWJM; Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands., Brouwers AH; Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands., Oprea-Lager DE; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands.; Department of Radiology and Nuclear Medicine, Radboud Medical Center, 6500 HK Nijmegen, The Netherlands., Oyen WJG; Department of Radiology and Nuclear Medicine, Radboud Medical Center, 6500 HK Nijmegen, The Netherlands.; Department of Biomedical Sciences, Humanitas University, 20090 Milan, Italy.; Department of Nuclear Medicine, Humanitas Clinical and Research Center, 20089 Milan, Italy.; Department of Radiology and Nuclear Medicine, Rijnstate, 6815 AD Arnhem, The Netherlands., Emmering J; Department of Radiology and Nuclear Medicine, Erasmus MC, 3000 KP Rotterdam, The Netherlands., Sieuwerts AM; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GE Rotterdam, The Netherlands., Jager A; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GE Rotterdam, The Netherlands., Kraan J; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GE Rotterdam, The Netherlands., Martens JWM; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GE Rotterdam, The Netherlands., de Vries EGE; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands., Sleijfer S; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GE Rotterdam, The Netherlands., Schröder CP; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute NKI-AvL, 1066 CX Amsterdam, The Netherlands. |
| Corporate Authors: | IMPACT-MBC Consortium |
| Source: | Diagnostics (Basel, Switzerland) [Diagnostics (Basel)] 2026 Apr 17; Vol. 16 (8). Date of Electronic Publication: 2026 Apr 17. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101658402 Publication Model: Electronic Cited Medium: Print ISSN: 2075-4418 (Print) Linking ISSN: 20754418 NLM ISO Abbreviation: Diagnostics (Basel) Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2075-4418 |
|---|---|
| DOI: | 10.3390/diagnostics16081197 |
